Minimal Residual Disease (MRD) Testing
News and reporting on minimal residual disease testing.
Genetron Health, Fosun Ink Commercialization Deal for Seq-MRD Test in China
The pharma firm is lending its large sales force to help promote the test across hospitals and clinics treating patients with hematologic cancers.
Princess Margaret Cancer Centre, Inivata Partner on Clinical Liquid Biopsy Studies
Inivata's InVisionFirst-Lung and RaDaR assays will support studies of the use of liquid biopsies in early and minimal residual disease detection.
Natera Builds Data Backing Serial ctDNA Changes to Aid CRC Patient Management, Treatment Decisions
Premium
The company believes its findings are the first to show that quantifying ctDNA changes can stratify high-risk colorectal cancer patients into better and worse prognostic groups.
Exact Sciences, NSABP Validating Ability of ctDNA Test to Detect MRD in Colorectal Cancer Patients
The study, called CORRECT-MRD II, is expected to enroll approximately 750 patients at 35 study sites in the US and Canada.
Natera Signatera Test to be Used in Study of MRD-Guided Treatment for Colon Cancer Patients
Patients will be randomized to receive various chemotherapy regimens depending on how Signatera identifies their minimal residual disease status.